USE OF THROMBOXANE ANTAGONIST IN CYCLOSPORIN A INDUCED RENAL TOXITY

摘要

PURPOSE: To reduce the renal toxicity of cyclosporine A by combining the cyclosporine A with a specific heptenoic acid of thromboxane receptor blocker. CONSTITUTION: This combination comprises cyclosporine A and [1R-[1(Z), 2,3,5]]-(+)-7[5-[[(1,1'-biphenyl)-4-yl]methoxy]-3-hydroxy-2(1-piperidinyl) cyclopentyl]-2heptenoic acid (hereinafter a compound A) or its physiologically permissible salt, solvate or cyclodextrin complex. The combination is used for the treatments of graft rejection and autoimmune disease and for the therapy of psoriasis and early insulin-dependent diabetes, and the cyclosporine A and the compound A are administered at daily doses of 5-25mg and 0.05-5mg, preferably 0.05-1mg, respectively, per kg of the body weight of a patient.